Education
About Us
Working with TipRanks
Follow Us
Fusion Antibodies Plc (GB:FAB)
:FAB
FAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range3.81p - 21.00p
Previous CloseN/A
Volume21.95K
Average Volume (3M)1.28M
Market Cap
£17.62M
Enterprise Value5.58M
Total Cash (Recent Filing)£359.00K
Total Debt (Recent Filing)£20.00K
Price to Earnings (P/E)―
Beta-1.01
Next Earnings
Sep 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,656,250
10 Day Avg. Volume1,114,569
30 Day Avg. Volume1,279,492
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.81
Price to Sales (P/S)3.00
P/FCF Ratio-4.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Fusion Antibodies Plc News
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 3.81p and its highest was 21.00p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £17.62M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Sep 04, 2025 which is 34 days ago.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Nov 19, 2024. The company reported -0.008p earnings per share for the quarter, missing the consensus estimate of N/A by -0.008p.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 113,656,250 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.008p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Technical Analysis
IXICO plc
―
Oxford BioDynamics
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---